BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-63@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — TQB3
 616 capsules\, Letrozole\, Anastrozole\, Tamoxifen [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Clinical Study on Adjuvant Therapy 
 of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined 
 With Endocrine Therapy in Patients With Breast Cancer.\nSource: https://cl
 inicaltrials.gov/study/NCT05780567\nhttps://catalystbrief.girapphe.com/e/6
 3?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/63?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
